Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.7 |
mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |